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Teaching Corner: The management of immune 
thrombocytopenic purpura  
Introduction
Thrombocytopenia, defined as a platelet count less than 100 
x 109/L, is common in clinical practice and poses diagnostic 
and management difficulties.
Haemostasis involves a delicate balance between 
procoagulant and anticoagulant mechanisms. The major 
components of  haemostasis are platelets, coagulation 
factors, coagulation inhibitors, fibrinolysis and blood vessels.1 
In severe thrombocytopenia, this haemostatic balance 
may be disturbed, leading to bleeding. Bleeding caused by 
thrombocytopenia is mucocutaneous and can present in 
different forms, which may include epistaxis, menorrhagia, 
petechiae, ecchymosis, subconjuctival haemorrhage and 
oozing of  blood from surgical incision sites.
Qualitative platelet disorders can also cause mucocutaneous 
bleeding. These qualitative platelet disorders can be hereditary 
or acquired. Acquired causes include uraemia in chronic renal 
disease and the antiplatelet action of   drugs, such as aspirin.2 
The pattern of  bleeding caused by coagulation disorders is 
quite different from that caused by platelet abnormalities. 
Bleeding resulting from coagulation disorders is characterised 
by bleeding into the joints, muscles, and connective tissue.1 
Definitive diagnosis of  qualitative platelet dysfunction 
cannot be made in Malawi; in our context, especially, the 
importance of  a good clinical history cannot be overstated.
Quantitative platelet disorders can be easily diagnosed from 
a full blood count that reveals thrombocytopenia. One cause 
of  thrombocytopenia is immune thrombocytopenic purpura 
(ITP), and this will be the topic of  discussion in this scholarly 
corner paper.
Mechanism of ITP
ITP is a heterogeneous disease characterised by increased 
platelet clearance and insufficient platelet production. 
Increased platelet destruction takes place in the tissue 
macrophages, predominantly in the spleen. Several 
features suggest the destruction of  platelets is mediated 
by the immunoglobulin fraction, IgG in particular, in the 
reticuloendothelial system. There is also inhibition of  platelet 
release by the platelet-making cells (megakaryocytes) in the 
bone marrow.3,4
What causes the initial development of  these antiplatelet 
antibodies is not clear, however sometimes a potential 
underlying cause, such as infection with hepatitis C, HIV, or 
Helicobacter pylori, is identified in some patients with immune 
thrombocytopenia.4,5
Platelet production is stimulated by thrombopoietin (TPO), 
which is secreted by the liver. In normal circumstances, 
the amount of  free TPO released into the circulation is 
constant at all times. As TPO molecules bind to TPO 
receptors on haemopoietic stem cells and megakaryocytes, 
they are internalized, degraded, and removed from the 
circulation. The levels of  free TPO are regulated by the 
number of  circulating platelets and the megakaryocyte 
mass. When platelet counts are low, excess free TPO is 
available for binding to megakaryocytes, causing an increase 
in thrombopoiesis; and when platelet counts are high, less 
free TPO is available for binding. TPO levels are usually 
normal or slightly decreased in ITP and not high, as might 
be expected.6,7 Normal TPO levels in the context of  ITP 
may be explained by the rapid clearance of  TPO from the 
circulation that results from increased platelet turnover (due 
to the presence platelet antibodies). In ITP, the number 
of  megakaryocytes is normal (and not increased) on bone 
marrow examination.7
Patients with ITP usually present with isolated 
thrombocytopenia. White cell count is usually normal, and 
haemoglobin is also normal, unless there has been significant 
blood loss related to the thrombocytopenia.
HIV-associated thrombocytopenia
Although mild to moderate thrombocytopenia is common in 
patients with HIV, it is rarely associated with bleeding. The 
main causes of  this thrombocytopenia are opportunistic 
infections, splenomegaly, and fever, which lead to decreased 
survival of  platelets.8 Platelet-associated antibodies increase 
in prevalence with HIV progression. These antibodies 
consist of  anti-glycoprotein II/Ia antibody. Some of  
these antibodies bind epitopes with homology to HIV-1 
proteins nef, gag, env, and pol, suggesting molecular mimicry.8 
These antibodies are present on the surface of  platelets in 
conditions such as sepsis and thrombotic thrombocytopenic 
purpura (TTP).
These platelet-associated antibodies deposit themselves on 
the platelet surface and promote early platelet removal by the 
liver and spleen.9 
For patients with advanced HIV disease, the thrombocytopenia 
is mainly caused by bone marrow failure. Defective 
megakaryopoiesis may also contribute to thrombocytopenia 
in advanced HIV disease. Megakaryocytes from HIV-1-
infected CD34+ progenitor cells are defective in their 
ability to produce platelets, as evidenced by hypercellular 
bone marrows with normal or increased numbers of  
megakaryocytes. These findings suggest that increased 
viral replication in the bone marrow microenvironment 
may cause this impairment and contribute to HIV-induced 
thrombocytopenia.8-10
Management of thrombocytopenia in HIV
Thrombocytopenia in HIV is rarely associated with bleeding 
and, for patients with platelet counts greater than 50 x 
109/L, no treatment is required. For some patients with 
clinically significant thrombocytopenia, short-term steroids 
produce a rapid response, but this has to be weighed against 
long-term infectious complications, as the steroids are 
immunosuppressive. Both antiretroviral agents and steroids 
improve thrombocytopenia by increasing platelet production 
without significantly affecting platelet survival.8,11,12
Evans syndrome
Patients can sometimes present with a combination of  
ITP and autoimmune haemolytic anaemia (AIHA). This 
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condition is known as Evans syndrome. Evans syndrome 
is defined by the combination of  (either simultaneously or 
sequentially) autoimmune haemolytic anaemia and immune 
thrombocytopenia, sometimes together with immune 
neutropenia, in the absence of  a known underlying cause. 
True Evans syndrome is a diagnosis of  exclusion and other 
confounding disorders should not be present.13
A patient with Evans syndrome may present with the usual 
features of  thrombocytopenia, such as petechiae, bruising, 
nose bleeding, gum bleeding, or menorrhagia; with or 
without features of  haemolytic anaemia, such as jaundice, 
pallor and, in severe cases, heart failure.13
A full blood count of  a patient with Evans syndrome 
will reveal the presence of  cytopenias and a blood film 
examination will reveal features of  haemolysis, such as red 
cell spherocytosis and polychromasia.
Management of ITP and Evans syndrome
The first-line therapy for ITP and Evans syndrome is 
corticosteroids. Prednisolone at a daily dose of  1 to 
2 mg/kg is generally used. Patients generally respond when 
treated with prednisolone, however the cytopenias may recur 
on tapering or cessation of  the steroids.13-16
For the patients in whom the conventional treatment 
with standard-dose corticosteroids is inappropriate, there 
are a wide variety of  medical therapies. These include: (i) 
ciclosporin at a dose of  5 mg/kg; (ii) cyclophosphamide at 
a dose of  1 to 2 mg/kg; (iii) azathioprine at a dose of  1 to 
2.5 mg/kg/day; (iv) oral high-dose dexamethasone 40 mg 
daily for four days, repeated every 28 days for six cycles; (vi) 
parenteral methyl prednisolone, 30 mg/kg/day for three 
days, then 20 mg/kg/day for four days, then tapering to 
5, 2, and 1 mg/kg/day each for one week; (vii) danazole 
at a dose of  200 mg two to four times; (viii) high-dose 
intravenous immunoglobulin, IVIG, at a dose of  1g/kg/day; 
(ix) anti-CD20 monoclonal antibody, rituximab, at a dose of  
375 mg/m2 and (x) intravenous anti-D, for RhD-positive 
patients who have not had splenectomy, at a dose of  50 to 
75 μg/kg. In ITP, anti-D is believed to work by preferentially 
destroying RhD-positive red cells through the spleen, thus 
sparing autoantibody-coated platelets.15,17,18
TPO receptor agonists, such as romiplostim and eltrombopag 
(both are licenced for treatment of  ITP) cause an increase in 
platelet count in ITP. One would expect that newly produced 
platelets, stimulated by TPO receptor agonists, would be 
rapidly destroyed by autoantibodies. It is believed that 
increased thrombopoiesis overcomes the autoantibodies; 
similarly, high doses of  platelet transfusion can temporarily 
increase platelet count in ITP.7
Splenectomy is traditionally used as a second-line therapy in 
patients who have failed to respond or relapsed following 
medical therapy with steroids.13-15
In Helicobacter pylori-associated ITP, eradication of  H. 
pylori leads to a significant increase in platelet count. The 
association between H. pylori and ITP is likely related to 
molecular mimicry, whereby the antibodies produced against 
the pathogens react with antigens on the surface of  platelets.4
In the acute setting, platelet and red cell transfusions may 
be required to alleviate symptoms, but their use should 
be minimized.13 The decision to transfuse platelets should 
be based on clinical and laboratory findings. Platelets are 
transfused to prevent or treat bleeding caused by platelet 
dysfunction. The total dose for platelets is 1 unit per 10 kg, 
and this total dose should be given rapidly over 15 to 30 
minutes.19
Childhood ITP and its management
The diagnosis of  childhood ITP is by exclusion. It can 
occur at anytime of  childhood, but in the neonatal period, 
it must be distinguished from maternal ITP or alloimmune 
thrombocytopenia.18 
In acute symptomatic ITP, the history is short with 
appearance of  bruising and purpura within 24 to 48 hours, 
and the platelet count is usually less than 20 x 109/L. This 
acute symptomatic ITP can be provoked by an acute viral 
infection or by immunization by the measles, mumps, and 
rubella (MMR) vaccine.18
ITP in children is uncommon and is usually transient. 
Childhood ITP is usually a benign disorder that requires no 
active management and serious bleeding is rare. About 80% 
of  the children will recover spontaneously within six to eight 
weeks.18,20
For children who require treatment because of  severe bleeding 
or to reduce the risk of  severe bleeding, the standard first-
line therapy in all the guidelines and consensus documents 
remains steroids. There is no consensus on dosing schedule, 
with some groups recommending a short course of  high-
dose prednisolone, 3 to 4 mg/kg/day for a maximum of  
four days and others recommending conventional doses of  
1 to 2 mg/kg/day for a maximum of  14 days.18,20
Thrombocytopenia in pregnancy
Thrombocytopenia occurs in 7% to 10% of  pregnancies. 
Diagnostic and management difficulties often arise in this 
context. Aetiologies include gestational thrombocytopenia 
(75%), thrombocytopenia secondary to hypertensive 
disorders (20%), thrombocytopenia as an immune process 
(4%), and others (1%).15,21 The diagnosis of  ITP involves 
exclusion of  other causes of  thrombocytopenia during 
pregnancy and normally does not involve bone marrow 
examination.
Management of ITP in pregnancy
Antenatal management of  ITP depends on the extent 
of  thrombocytopenia. Bleeding episodes caused by 
thrombocytopenia are less common in pregnant women than 
in non-pregnant women, as pregnancy is a hypercoagulable 
state, associated with increased levels of  fibrinogen, factor 
VIII, and von Willebrand factor (vWF). There is also 
suppressed fibrinolysis and reduction in the activity of  
protein S, which is a natural anticoagulant.15,21
The aim of  ITP management in pregnancy is to achieve 
and maintain “safer” rather than normal platelet counts. In 
the first two trimesters, asymptomatic patients with platelet 
counts greater than 20 to 30 x 109/L do not need any 
treatment until the third trimester. Treatment is required if  
platelet counts fall below 20 to 30 x 109/L, when the patient 
is symptomatic, or when there is a need to increase platelet 
count to a level considered safe for a procedure. A platelet 
count of  50 x 109/L is usually safe for a procedure.
Antenatal full blood counts can be checked monthly until 
the third trimester and then two-weekly, then weekly as term 
approaches.21
For those who require treatment, the usual first-line treatment 
is prednisolone, but at much lower doses: 20 to 30 mg per 
day for a week. Although prednisolone is metabolized in 
the placenta by 11-beta-hydroxylase, high doses may have 
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adverse effects on the pregnancy or foetus, including 
premature rupture of  membranes, adrenal suppression, 
and a slightly increased risk of  cleft lip after use in the first 
trimester. Platelet counts may fall more rapidly near term, so 
defer tapering of  steroids until after delivery.15,21
The mode of  delivery should be based on obstetric 
considerations. From 35 to 36 gestational weeks, or prior 
to any intervention, give treatment to raise platelet counts 
to at least 50 x 109/L and aim to attain a platelet count of  
more than 80 x 109/L to allow for regional anaesthesia, as 
many anaesthetists would not consider an epidural below 
this level.15
Where the maternal platelet count remains below 50 x 109/L 
around the time of  delivery, platelets for transfusion should 
be available on standby. Platelets should be transfused during 
well-established labour and if  there are increased bleeding 
complications.15
Differential diagnoses of thrombocytopenia
As stated earlier, ITP is just one of  the causes of  
thrombocytopenia. When faced with a patient with 
thrombocytopenia, it is important to know that there are 
other possible causes. The other causes of  thrombocytopenia 
include: (i) infections such as malaria and sepsis; (ii) 
disseminated intravascular coagulation (DIC); (iii) thrombotic 
thrombocytopenic purpura/haemolytic uremic syndrome 
(TTP/HUS); and (iii) heparin-induced thrombocytopenia 
(HIT).
ITP can sometimes be diagnosed incidentally if  the patient 
does not have mucocutaneous bleeding, while TTP/HUS 
is a haematological emergency, with patients presenting 
critically ill.
Thrombotic thrombocytopenic purpura/haemolytic 
uraemic syndrome (TTP/HUS)
Thrombotic thrombocytopenic purpura and haemolytic 
uraemic syndrome are two different disorders with disparate 
pathogenetic mechanisms; however, they have very similar 
presentations and thus are grouped into the single designation 
TTP/HUS. HUS is caused by Shiga toxin-producing 
strains of  Escherichia coli and Shigella dysenteriae. TTP has a 
predilection for young females in their thirties with advanced 
HIV and is less frequent in those on antiretroviral therapy. 
Novitzky et al. reported that patients with HIV-associated 
TTP were exclusively of  the African Black race and that they 
were mainly women.22 It is caused by IgG autoantibodies to a 
vWF-cleaving enzyme called ADAMTS13 (a disintegrin-like 
metalloprotease with thrombospondin type 1 motif  13).22-25 
TTP and HUS are characterised by the formation of  thrombi 
in the arterioles and capillaries and a pentad of  symptoms 
and signs, which are thrombocytopenia, microangiopathic 
haemolytic anaemia, neurologic abnormalities, renal failure, 
and fever. Coombs test is negative. In TTP, thrombocytopenia 
and haemolysis are caused by clumping of  platelets and 
shearing of  red cells by mechanical damage, while in HUS 
they are caused by the direct cytotoxic effects of  Shiga toxin 
and complement activation.
Management of TTP/HUS
Plasmapheresis (plasma exchange) is the standard treatment 
of  TTP, as it removes the autoantibodies against the vWF-
cleaving enzyme and replaces the fresh enzyme. This 
treatment requires expensive equipment and skilled operators, 
both of  which are not available in most developing countries, 
including Malawi. Fresh frozen plasma (FFP) infusions at a 
dose of  30 mL/kg/day (± diuresis with frusemide) in three 
divided doses (provided the patient can tolerate the volume 
load) can be effective.22 
Heparin-induced thrombocytopenia (HIT)
Heparin-induced thrombocytopenia is a potentially serious 
drug adverse effect more frequently associated with 
unfractionated heparin (UFH) than low molecular weight 
heparin (LMWH). Heparin induces platelet activation and 
aggregation and activates the coagulation system. HIT does 
not usually cause bleeding, but instead causes thrombosis.26 
Management of  HIT includes withdrawing the heparin and 
the use of  an alternative anticoagulant, such as streptokinase, 
when acute venous or arterial thrombosis is present.26 In the 
presence of  severe or extending thrombosis, commencement 
of  warfarin should be delayed for a few days, as protein C 
and protein S reduction induced by warfarin can lead to 
thrombus progression.26
Disseminated intravascular coagulation (DIC)
Disseminated intravascular coagulation (DIC) never occurs 
in isolation, and it is associated with a range of  illnesses and 
conditions. These include sepsis, trauma, malignancy, ABO 
transfusion incompatibility, and obstetric and gynaecological 
conditions, such as amniotic fluid embolism, placental 
abruption, and pre-eclampsia.27 DIC is characterised 
by generalised intravascular activation of  haemostatic 
mechanisms, leading to widespread fibrin clot formation, 
consumption of  platelets and coagulation factors, and 
activation of  fibrinolysis.27
Diagnosis of disseminated intravascular coagulation
Diagnosis of  DIC requires clinical and laboratory information. 
The patient should have an underlying condition known to 
be associated with a DIC. Laboratory tests should include 
full blood count (to note the trend of  platelet reduction: a 
continuous drop in platelet count, even if  the count is within 
the normal range of  150 to 400 x109/L, may indicate DIC); 
prothrombin time (PT), and activated partial thromboplastin 
time (aPTT), which are prolonged in the context of  increased 
consumption of  coagulation factors.27,28
The International Society on Thrombosis and Haemostasis 
(ISTH) recommends the use of  scoring systems for overt 
DIC and non-overt DIC.29
Scoring system for overt DIC:
1.Risk assessment: Does the patient have an underlying 
disorder known to be associated with overt DIC?
If  yes: proceed
If  not: do not use this algorithm
2. Order global coagulation tests (platelet count, PT, 
fibrinogen, fibrin-related marker)
3.Score the global coagulation test results
• Platelet count (>100 = 0; < 100 = 1; < 50 = 2)
• Prolonged PT (< 3 s = 0; > 3 but < 6 s = 1; > 6 s = 2)
• Elevated fibrin marker (e.g., D-dimer, fibrin degradation 
products) (no increase = 0; moderate increase = 1; strong 
increase = 2)
• Fibrinogen level (> 1 = 0; < 1 = 1)
4. Calculate score:
• Scores ≥ 5 are compatible with overt DIC: repeat score 
daily
• Scores < 5 are suggestive of  non-overt DIC: repeat 
next 1 to 2 days
Malawi Medical Journal; 27(3): 109-112 September 2015 Teaching Corner: Management of ITP 112
http://dx.doi.org/10.4314/mmj.v27i3.8
References
1. Hoffbrand AV, Pettit JE, Moss PAH. Essential haematology. 4th ed. 
Williston, Vermont, USA: Wiley-Blackwell; 2002.
2. Lichtman MA, Beutler E, Kaushansky K, Kipps TJ, Seligsohn U, 
Prchal J. Williams hematology. 7th ed. New York: McGraw-Hill; 2005.
3. Cines DB, McMillan R. Pathogenesis of chronic immune 
thrombocytopenia. Curr Opin Hematol. 2007;14(5):511-4.
4. Cooper N, Bussel J. The Pathogenesis of immune thrombocytopenia. 
Br J Haematol. 2006;133(4):364-74.
5. Cines DB, Bussel J, Liebman HA, Luning Prak ET. The ITP 
syndrome: pathogenesis and clinical diversity. Blood. 2009 Jun 
25;113(26):6511-21. doi: 10.1182/blood-2009-01-129155.
6. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of 
chronic immune thrombocytopenia: increased platelet destruction and/
or decreased platelet production. Br J Haematol. 2009 Sep;146(6):585-
96. doi: 10.1111/j.1365-2141.2009.07717.x.
7. Toltl LJ, Arnold DM. Pathophysiology and management of chronic 
immune thrombocytopenia: focusing on what matters. Br J Haematol. 
2011 Jan;152(1):52-60. doi: 10.1111/j.1365-2141.2010.08412.x.
8. Sloand E. Haematologic complications of HIV infection. AIDS 
Reviews. 2005;7:187-96.
9. Sloand EM, Klein HG, Banks SM, Vareldzis B, Merrit S, Pierce P. 
Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol. 
1992 Mar;48(3):168-72.
10. Zauli G, Re M, Davis B, Sen L, Visani G, Gugliotta L, et al. Impaired 
in vitro growth of purified (CD34+) haematopoietic progenitors in 
HIV-1 seropositive thrombocytopenic individuals. Blood. 1992 May 
15;79(10):2680-7.
11. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of 
Response to Treatment in Autoimmune Thrombocytopenic Purpura. N 
Engl J Med. 1989 Apr 13;320(15):974-80.
12. Ballem PJ, Belzberg A, Devine DV, Lyster D, Spruston B, Chambers 
H, et al. Kinetic studies of the mechanism of thrombocytopenia in 
patients with Human Immunodeficiency Virus infection. N Engl J Med. 
1992 Dec 17;327(25):1779-84.
13. Norton A, Roberts I. Management of Evans syndrome. Br J 
Haematol. 2006 Jan;132(2):125-37.
14. McVerry BA. Management of idiopathic thrombocytopenic 
purpura. Br J Haematol. 1985 Feb;59(2):203-8.
15. Myers B. Diagnosis and management of maternal thrombocytopenia 
in pregnancy. Br J Haematol. 2012 Jul;158(1):3-15. doi: 10.1111/j.1365-
2141.2012.09135.x.
16. Ghanima W, Godeau B, Cines DB and Bussel BJ. How I treat 
immune thrombocytopenia: the choice between splenectomy or 
a medical therapy as a second-line treatment. Blood. 2012 Aug 
2;120(5):960-9. doi: 10.1182/blood-2011-12-309153.
17. Gibbon, CJ, editor. South African medicines formulary. 6th ed. 
Pinelands, South Africa: The South African Medical Association Health 
and Medical Publishing Group. 2003.
18. British Committee for Standards in Haematology General 
Haematology Task Force. Guidelines for the investigation and 
management of idiopathic thrombocytopenic purpura in adults, children 
and in pregnancy. Br J Haematol. 2003 Feb;120(4):574-96.
19. Chosamata BI, M’baya B, Njolomole S. Guidelines for the clinical 
use of blood and blood products in Malawi. 1st ed. Lilongwe: Ministry 
of Health, Malawi; 2012.
20. Cooper N. A review of the management of childhood immune 
thrombocytopenia: how can we provide an evidence-based approach? 
Br J Haematol. 2014 Jun;165(6):756-67. doi: 10.1111/bjh.12889.
21. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, 
Busse JB, et al. International consensus report on the investigation and 
management of primary immune thrombocytopenia. Blood. 2010 Jan 
14;115(2):168-86. doi: 10.1182/blood-2009-06-225565.
22. Novitzky N, Thomson J, Abrahams L, du Toit C, McDonald A. 
Thrombotic thrombocytopenic purpura in patients with retroviral 
infection is highly responsive to plasma infusion therapy. Br J Haematol. 
2005 Feb;128(3):373-9.
23. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 
2005 Jul 1;106(1):11-7.
24. Derad I, Obermann B, Katalinic A, Eisemann N, Knobloch JK, Sayk 
F, et al. Hypertension and mild chronic kidney disease persist following 
severe haemolytic uraemic syndrome caused by Shiga toxin-producing 
Escherichia coli O104:H4 in adults. Nephrol Dial Transplant. 2015 Jul 
14;0:1-9. doi: 10.1093/ndt/gfv255
25. Hwang WY, Chai LY, Ng HJ, Goh YT, Tan PH. Therapeutic 
plasmapheresis for the treatment of the thrombotic thrombocytopenic 
purpura-haemolytic uraemic syndromes. Singapore Med J. 2004 
May;45(5):219-23.
26. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost. 
2003 Jul;1(7):1471-8.
27. Levi M, Toh CH, Thachil J, Watson HG; British Committee 
for Standards in Haematology. Guidelines for the diagnosis and 
management of disseminated intravascular coagulation. Br J Haematol. 
2009 Apr;145(1):24-33. doi: 10.1111/j.1365-2141.2009.07600.x.
28. Provan D, Singer CRJ, Baglin T and Lilleyman J, eds. Oxford 
handbook of clinical hematology. 2004, Oxford University Press.
29. Toh CH, Hoots WK; SSC on Disseminated Intravascular 
Coagulation of the ISTH.. The scoring system of the scientific and 
standardisation committee on disseminated intravascular coagulation 
of the International Society on Thrombosis and Haemostasis: a 5-year 
overview. J Thromb Haemost. 2007 Mar;5(3):604-6.
